<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37298160</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9210</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24119210</ELocationID><Abstract><AbstractText>Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase-deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for SLE and APS diagnosis and their association with clinical features and disease activity. A total of 138 people were included in the cross-sectional study: 30 with SLE without APS, 47 with SLE and APS, 41 patients with primary antiphospholipid syndrome (PAPS), and 20 seemingly healthy individuals. Serum MPO-DNA complex and nucleosome levels were determined via an enzyme-linked immunosorbent assay (ELISA). Informed consent was obtained from all subjects involved in the study. The Ethics Committee of the V.A. Nasonova Research Institute of Rheumatology (Protocol No. 25 dated 23 December 2021) approved the study. In patients with SLE without APS, the levels of the MPO-DNA complex were significantly higher compared to patients with SLE with APS, with PAPS, and healthy controls (<i>p</i> &lt; 0.0001). Among patients with a reliable diagnosis of SLE, 30 had positive values of the MPO-DNA complex, of whom 18 had SLE without APS, and 12 had SLE with APS. Patients with SLE and positive MPO-DNA complex levels were significantly more likely to have high SLE activity (&#x3c7;<sup>2</sup> = 5.25, <i>p</i> = 0.037), lupus glomerulonephritis (&#x3c7;<sup>2</sup> = 6.82, <i>p</i> = 0.009), positive antibodies to dsDNA (&#x3c7;<sup>2</sup> = 4.82, <i>p</i> = 0.036), and hypocomplementemia (&#x3c7;<sup>2</sup> = 6.72, <i>p</i> = 0.01). Elevated MPO-DNA levels were observed in 22 patients with APS: 12 with SLE with APS and 10 with PAPS. There were no significant associations between positive levels of the MPO-DNA complex and clinical and laboratory manifestations of APS. The concentration of nucleosomes was significantly lower in the group of SLE patients (&#xb1;APS) compared to controls and PAPS (<i>p</i> &lt; 0.0001). In SLE patients, the frequency of low nucleosome levels was associated with high SLE activity (&#x3c7;<sup>2</sup> = 13.4, <i>p</i> &lt; 0.0001), lupus nephritis (&#x3c7;<sup>2</sup> = 4.1, <i>p</i> = 0.043), and arthritis (&#x3c7;<sup>2</sup> = 3.89, <i>p</i> = 0.048). An increase in the specific marker of NETosis, the MPO-DNA complex, was found in the blood serum of SLE patients without APS. Elevated levels of the MPO-DNA complex can be regarded as a promising biomarker of lupus nephritis, disease activity, and immunological disorders in SLE patients. Lower levels of nucleosomes were significantly associated with SLE (&#xb1;APS). Low nucleosome levels were more common in patients with high SLE activity, lupus nephritis, and arthritis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reshetnyak</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3552-2522</Identifier><AffiliationInfo><Affiliation>V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nurbaeva</LastName><ForeName>Kamila</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ptashnik</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudriaeva</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belogurov</LastName><ForeName>Alexey</ForeName><Initials>A</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Chemistry, Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russian Federation, 127473 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lila</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasonov</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009707">Nucleosomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009707" MajorTopicYN="N">Nucleosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="Y">Arthritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MPO-DNA complex</Keyword><Keyword MajorTopicYN="N">NETosis</Keyword><Keyword MajorTopicYN="N">antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">nephritis</Keyword><Keyword MajorTopicYN="N">nucleosomes</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>There are no conflict of interest. All the authors have participated in writing the manuscript. Its final version has been approved by all the authors. The authors have not received fees for the article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37298160</ArticleId><ArticleId IdType="pmc">PMC10252548</ArticleId><ArticleId IdType="doi">10.3390/ijms24119210</ArticleId><ArticleId IdType="pii">ijms24119210</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nasonov E.L., Soloviev S.K., Arshinov A.V. Systemic lupus erythematosus: History and modernity. Rheumatol. Sci. Pract. 2022;60:397&#x2013;412. doi: 10.47360/1995-4484-2022-397-412. (In Russian)</Citation><ArticleIdList><ArticleId IdType="doi">10.47360/1995-4484-2022-397-412</ArticleId></ArticleIdList></Reference><Reference><Citation>Reshetnyak T.M., Cheldieva F.A., Nurbaeva K.S., Lila A.M., Nasonov E.L. Antiphospholipid syndrome: Diagnosis, mechanism of development, issues of therapy. Thromb. Hemost. Rheol. 2020;4:4&#x2013;21. doi: 10.25555/THR.2020.4.0940. (In Russian)</Citation><ArticleIdList><ArticleId IdType="doi">10.25555/THR.2020.4.0940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim A.A.G., Shadi H.W.E., Elamin A.A.Y., Draz H.E. Retrospective cohort study of thromboembolic events in systemic lupus erythematosus with or without secondary antiphospholipid syndrome and their correlation to lupus activity and dyslipidemia. Egypt. Rheumatol. Rehabil. 2023;50:10. doi: 10.1186/s43166-023-00175-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43166-023-00175-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirestam L., Arve S., Linge P., Bengtsson A.A. Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Front. Immunol. 2019;10:2734. doi: 10.3389/fimmu.2019.02734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02734</ArticleId><ArticleId IdType="pmc">PMC6882868</ArticleId><ArticleId IdType="pubmed">31824510</ArticleId></ArticleIdList></Reference><Reference><Citation>Fousert E., Toes R., Desai J. Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses. Cells. 2020;9:915. doi: 10.3390/cells9040915.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040915</ArticleId><ArticleId IdType="pmc">PMC7226846</ArticleId><ArticleId IdType="pubmed">32276504</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K., Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 2021;18:666&#x2013;682. doi: 10.1038/s41569-021-00552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00552-1</ArticleId><ArticleId IdType="pmc">PMC8100938</ArticleId><ArticleId IdType="pubmed">33958774</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoimenou M., Tzorosm G., Skendros P., Chrysanthopoulou A. Methods for the Assessment of NET Formation: From Neutrophil Biology to Translational Research. Int. J. Mol. Sci. 2022;23:15823. doi: 10.3390/ijms232415823.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232415823</ArticleId><ArticleId IdType="pmc">PMC9781911</ArticleId><ArticleId IdType="pubmed">36555464</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S., Nakazawa D., Shida H., Miyoshi A., Kusunoki Y., Tomaru U., Ishizu A. NETosis markers: Quest for specific, objective, and quantitative markers. Clin. Chim. Acta. 2016;459:89&#x2013;93. doi: 10.1016/j.cca.2016.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.05.029</ArticleId><ArticleId IdType="pubmed">27259468</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdalla M.A., Elmofty S.A., Elmaghraby A.A., Khalifa R.H. Anti-nucleosome antibodies in systemic lupus erythematosus patients: Relation to anti-double stranded deoxyribonucleic acid and disease activity. Egypt. Rheumatol. 2018;40:29&#x2013;33. doi: 10.1016/j.ejr.2017.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2017.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi F., Giaglis S., Hahn S., Blum C.A., Baumgartner C., Kutz A., van Breda S.V., Mueller B., Schuetz P., Christ-Crain M., et al. Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: Secondary analysis of a randomised controlled trial. Eur. Respir. J. 2018;51:1701389. doi: 10.1183/13993003.01389-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01389-2017</ArticleId><ArticleId IdType="pubmed">29519921</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil Extracellular Traps Kill Bacteria. Science. 2004;303:1532&#x2013;1535. doi: 10.1126/science.1092385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092385</ArticleId><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson P.C., Kaplan M.J. At the Bench: Neutrophil extracellular traps (NETs) high-light novel aspects of innate immune system involvement in autoimmune diseases. J. Leukoc. Biol. 2016;99:253&#x2013;264. doi: 10.1189/jlb.5BT0615-247R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.5BT0615-247R</ArticleId><ArticleId IdType="pmc">PMC4718195</ArticleId><ArticleId IdType="pubmed">26432901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanata N., Ota M., Tsuchida Y., Nagafuchi Y., Okamura T., Shoda H., Fujio K. Serum extracellular traps associate with the activation of myeloid cells in SLE patients with the low level of anti-DNA antibodies. Sci. Rep. 2022;12:18397. doi: 10.1038/s41598-022-23076-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23076-1</ArticleId><ArticleId IdType="pmc">PMC9626644</ArticleId><ArticleId IdType="pubmed">36319843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M., Bonanni A., Petretto A., Vaglio A., Pratesi F., Santucci L., Migliorini P., Bertelli R., Galetti M., Belletti S., et al. Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. J. Rheumatol. 2020;47:377&#x2013;386. doi: 10.3899/jrheum.181232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.181232</ArticleId><ArticleId IdType="pmc">PMC6917988</ArticleId><ArticleId IdType="pubmed">31092713</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden M., van den Hoogen L.L., Westerlaken G.H.A., Fritsch-Stork R.D.E., van Roon J.A.G., Radstake T.R.D.J., Meyaard L. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology. 2018;57:1228&#x2013;1234. doi: 10.1093/rheumatology/key067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key067</ArticleId><ArticleId IdType="pubmed">29608758</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Ghoneimy D.H., Hesham M., Hasan R., Tarif M., Gouda S. The behavior of neutrophil extracellular traps and NADPH oxidative activity in pediatric systemic lupus erythematosus: Relation to disease activity and lupus nephritis. Clin. Rheumatol. 2019;38:2585&#x2013;2593. doi: 10.1007/s10067-019-04547-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04547-9</ArticleId><ArticleId IdType="pubmed">31030361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim A., F&#xfc;rnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., Herrmann M., Voll R.E., Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA. 2010;107:9813&#x2013;9818. doi: 10.1073/pnas.0909927107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId><ArticleId IdType="pmc">PMC2906830</ArticleId><ArticleId IdType="pubmed">20439745</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J., Martin M., Gullstrand B., Tyd&#xe9;n H., Lood C., Truedsson L., Bengtsson A.A., Blom A.M. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 2012;188:3522&#x2013;3531. doi: 10.4049/jimmunol.1102404.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102404</ArticleId><ArticleId IdType="pubmed">22345666</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J., Gullstrand B., J&#xf6;nsen A., Nilsson J., Martin M., Blom A.M., Bengtsson A.A. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2013;15:R84. doi: 10.1186/ar4264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4264</ArticleId><ArticleId IdType="pmc">PMC3978901</ArticleId><ArticleId IdType="pubmed">23945056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Lu X., Shu X., Tian X., Yang H., Yang W., Zhang Y., Wang G. Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. Intern. Med. 2014;53:2763&#x2013;2771. doi: 10.2169/internalmedicine.53.2570.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.53.2570</ArticleId><ArticleId IdType="pubmed">25500436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremic I., Djuric O., Nikolic M., Vlajnic M., Nikolic A., Radojkovic D., Bonaci-Nikolic B. Neutrophil extracellular traps-associated markers are elevated in patients with systemic lupus erythematosus. Rheumatol. Int. 2019;39:1849&#x2013;1857. doi: 10.1007/s00296-019-04426-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04426-1</ArticleId><ArticleId IdType="pubmed">31444555</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Li A.M., Rubin C.J., Zhao W., Olsen S.H., Klinker M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011;187:538&#x2013;552. doi: 10.4049/jimmunol.1100450.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId><ArticleId IdType="pmc">PMC3119769</ArticleId><ArticleId IdType="pubmed">21613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Xiao S., Xia Y., Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clinic. Rev. Allergy Immunol. 2022;63:152&#x2013;165. doi: 10.1007/s12016-021-08898-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08898-7</ArticleId><ArticleId IdType="pmc">PMC9464114</ArticleId><ArticleId IdType="pubmed">34542806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pati&#xf1;o-Trives A.M., P&#xe9;rez-S&#xe1;nchez C., P&#xe9;rez-S&#xe1;nchez L., Luque-T&#xe9;var M., &#xc1;balos-Aguilera M.C., Alcaide-Ruggiero L., Arias-de la Rosa I., Rom&#xe1;n-Rodr&#xed;guez C., Segu&#xed; P., Espinosa M., et al. Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arterioscler. Thromb. Vasc. Biol. 2021;41:2417&#x2013;2430. doi: 10.1161/ATVBAHA.121.315928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.121.315928</ArticleId><ArticleId IdType="pubmed">34320837</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bont C.M., Boelens W.C., Pruijn G.J.M. NETosis, complement, and coagulation: A triangular relationship. Cell. Mol. Immunol. 2019;16:19&#x2013;27. doi: 10.1038/s41423-018-0024-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0024-0</ArticleId><ArticleId IdType="pmc">PMC6318284</ArticleId><ArticleId IdType="pubmed">29572545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai M. Systemic lupus erythematosus and nucleosome. Nihon Rinsho Meneki Gakkai Kaishi. 2006;29:127&#x2013;135. doi: 10.2177/jsci.29.127. (In Japanese)</Citation><ArticleIdList><ArticleId IdType="doi">10.2177/jsci.29.127</ArticleId><ArticleId IdType="pubmed">16819261</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoura Z., Piette J.C., Chabre H., Cacoub P., Papo T., Wechsler B., Bach J.F., Koutouzov S. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum. 1997;40:2217&#x2013;2225. doi: 10.1002/art.1780401217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780401217</ArticleId><ArticleId IdType="pubmed">9416860</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R.C., Jr., Malone C.C., Meyers C., Decker P., Muller S. Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7. J. Rheumatol. 2001;28:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsman G., Stephan F., de Leeuw K., Bulder I., Ruinard J.T., de Jong J., Westra J., Bultink I.E., Voskuyl A.E., Aarden L.A., et al. FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE. Eur. J. Immunol. 2016;46:762&#x2013;771. doi: 10.1002/eji.201546010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201546010</ArticleId><ArticleId IdType="pubmed">26626052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalavarthi S., Gould T.J., Rao A.N., Mazza L.F., Morris A.E., N&#xfa;&#xf1;ez-&#xc1;lvarez C., Hern&#xe1;ndez-Ram&#xed;rez D., Bockenstedt P.L., Liaw P.C., Cabral A.R., et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67:2990&#x2013;3003. doi: 10.1002/art.39247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39247</ArticleId><ArticleId IdType="pmc">PMC4626310</ArticleId><ArticleId IdType="pubmed">26097119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hell L., Lurger K., Mauracher L.-M., Grilz E., Reumiller C.M., Schmidt G.J., Ercan H., Koder S., Assinger A., Bas&#xed;lio J., et al. Altered platelet proteome in lupus anticoagulant (LA)-positive patients-protein disulfide isomerase and NETosis as new players in LA-related thrombosis. Exp. Mol. Med. 2020;52:66&#x2013;78. doi: 10.1038/s12276-019-0358-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0358-4</ArticleId><ArticleId IdType="pmc">PMC7000701</ArticleId><ArticleId IdType="pubmed">31956273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazetto B.D.M., Hounkpe B.W., Saraiva S.D.S., Vieira-Damiani G., dos Santos A.P.R., Jacinto B.C., Vaz C.D.O., Mesquita G.T.V., Annichino-Bizzacchi J.M., De Paula E.V., et al. Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. Thromb. Res. 2022;214:132&#x2013;137. doi: 10.1016/j.thromres.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.05.001</ArticleId><ArticleId IdType="pubmed">35561448</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Zuo Y., Zhang S., Makris U.E., Karp D.R., Li Z. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients. Chin. Med. J. 2022;135:658&#x2013;664. doi: 10.1097/CM9.0000000000001964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001964</ArticleId><ArticleId IdType="pmc">PMC9276217</ArticleId><ArticleId IdType="pubmed">35143425</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z., Urowitz M.B., Ibanez D., Gladman D.D. Sledai-2k 10 days versus sledai-2k 30 days in a longitudinal evaluation. Lupus. 2011;20:67&#x2013;70. doi: 10.1177/0961203310385163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310385163</ArticleId><ArticleId IdType="pubmed">21233149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Goldsmith C.H., Urowitz M.B., Bacon P., Fortin P., Ginzler E., Gordon C., Hanly J.G., Isenberg D.A., Petri M., et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J. Rheumatol. 2000;27:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10685799</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H.W.M., De Groot P.G., Koike T., Meroni P.L., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleksandrova E.N., Novikov A.A., Reshetnyak T.M., Nasonov E.L. Antibodies to &#x3b2;2-glycoprotein 1 and antibodies to cardiolipin in antiphospholipid syndrome: Sensitivity and specificity analysis. Klin. Meditsina. 2003;81:25&#x2013;31. (In Russian)</Citation><ArticleIdList><ArticleId IdType="pubmed">14598587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>